成大生物：子公司高剂量流感疫苗获批临床试验，适用于老年人群预防流感

Core Viewpoint - Chengda Biotech's subsidiary has received approval from the National Medical Products Administration for clinical trials of a high-dose influenza virus split vaccine aimed at preventing influenza in individuals aged 60 and above [1] Group 1: Company Developments - Chengda Biotech's subsidiary, Chengda Biotech (Benxi) Co., Ltd., has been granted a Clinical Trial Approval Notice for a high-dose influenza vaccine [1] - The vaccine is classified as a Class 3.2 biological product for preventive use, specifically targeting the elderly population [1] Group 2: Market Potential - The effective component of the vaccine is four times the dosage of the standard influenza vaccine, indicating a potentially higher efficacy [1] - The vaccine has already been approved for market use in several countries and regions, suggesting a strong market demand [1]